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Abstract 
Cyclosporine A-nanosuspensions were prepared using zirconium oxide beads 
as a milling media, Poloxamer 407 as a stabilizer and distilled water as an 
aqueous medium using the Pearl Milling technique. The optimized formulation 
was characterized in terms of particle size distribution, surface morphology, 
drug-surfactant interaction, drug content, saturation solubility, osmolarity, and 
stability. The nanoparticles consisting of Poloxamer-bound cyclosporin A with a 
mean diameter of 213 nm revealed a spherical shape and 5.69 fold increased 
saturation solubility as compared to the parent drug. The formulation was found 
to be iso-osmolar with blood and stable up to 3 months at 2–8°C. In-vivo studies 
were carried out in albino rats and the pharmacokinetic parameters were 
compared with a marketed formulation, which indicated better results of the 
prepared formulation than the marketed one. 
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Introduction 
Cyclosporine A, a neutral hydrophobic cyclic peptide composed of 11 amino acid residues, 
is a 3
rd generation immunosuppressant, used in organ transplantation since 1981 [1, 2].
 
The aqueous solubility of CsA is very low and it displays a considerable inter and intra 
patient variability presumably due to its poor and highly bile dependent absorption as well 
as intestinal metabolism. Hence therapy requires careful monitoring of blood levels [3].
 
Exceeding the therapeutic window adverse effects like nephrotoxicity and hepatotoxicity 
are reported. Furthermore it has been reported that at sub therapeutic drug levels, organ 
transplantation rejection occurs after systemic drug administration in case of lung, heart-
lung or corneal transplantation [4]. 
Major efforts have concentrated on development of customized drug carriers to overcome 
the disappointing in vivo characteristics of the drug. For carriers non-toxicity (acute and 
chronic), sufficient drug loading capacity, possibility of drug targeting, controlled release 
characteristics, chemical and physical storage stability (for both drug and carrier) and 
feasibility of scaling up production with reasonable overall costs are requested [5–7]. 
Colloidal carriers have attracted the main interest because they are promising systems to 
fulfill the requirements mentioned above. But in the first place, nanosized carriers are 
treated as a hopeful means to increase the solubility and therefore the bioavailability of 
poorly water-soluble active ingredients belonging to the classes II and IV in the 
Biopharmaceutical Classification System (BCS) [8–10]. Scaling up production at 
reasonable overall costs are requested. In conventional dosage forms of CsA, available at 
the market as sandimmune®, Cremophor EL (polyoxyethylated castor oil) is used as a 
solubilizer associated with the major problems of Cremophor EL such as anaphylactic 
shock. In addition vascular collapse due to nephrotoxicity and hemolysis as well as 
respiratory distress related release of histamine can occur as side-effects [3, 11]. 
Recently, it has been found that the majority of the water insoluble drugs belong to the 
group of anti-cancer agents, anti-infectiva, central nervous system (CNS) and anti-viral 
therapeutics. With the increasing incidence of these diseases, there has been a strong 
interest in nanosuspension dosage forms for injectable applications evolved. Following the 
approval of a nanoparticulate i.v dosage form, Abraxane® (130 nm amorphous particles of 
paclitaxel entrapped in human serum albumin), in 2005, there has been a steady increase 
in the drug nanoparticulate formulations entering clinical trials [12]. An important 
advantage of the drug nanosuspensions is their administration via various routes, such as 
oral [13], parenteral [14], ocular [15] and pulmonary delivery [16]. In addition, nano-
suspensions have been shown superior to their counterparts of formulated traditionally in 
every administration route. For nanosuspensions, according to Noyes–Whitney and 
Ostwald–Freundlich equation, particle size in nanometer range can lead to increased 
dissolution velocity and saturation solubility [17,  18] so that oral absorption of poorly 
soluble drugs together with higher bioavailability can be achieved as compared to the 
traditional formulation [13,19]. Beyond that, due to their sufficiently small size and safe 
composition, nanosuspensions can be injected intravenously, and 100% bioavailability can 
be reached [20].  
The present work is carried out to overcome the toxicity caused by Cremophore EL 35 that 
is currently used in conventional formulations and to minimize, the P-Glycoprotein 
mediated drug- efflux by developing a stable nanosuspension of CsA.    Cyclosporine A-Nanosuspension: Formulation, Characterization and In Vivo Comparison with …  347 
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Tab. 1.   Optimization of the parameters for the preparation of CsA-nanosuspensions  
Batch 
No. 
Conc. of 
drug 
(% w/v) 
Conc. 
Surfact-
ant 
(Poloxa-
mer 407) 
% v/v of 
Milling 
Media 
(ZrO2 
beads) 
Particle size 
before 
Lyophillizatio
n [d(4,3)] 
Uni-
formity
Particle size 
after Lyophil-
lization [d(4,3)] 
Uni-
formity 
CMM-1 1  3.0  50  0.227µm  0.260  0.237µm  0.289 
CMM-2 1  3.0  40  0.217µm  0.253  0.235µm  0.284 
CMM-3 1  3.0  60  0.262µm  0.361  0.351µm  0.663 
CMM-4 1  2.5  50  0.294µm  0.369  0.565µm  1.33 
CMM-5 1  2.5  40  0.213µm  0.245  0.216µm  0.250 
CMM-6 1  2.5  60  0.737µm  1.98  1.242µm  5.43 
CMM-7 1  3.5  50  0.263µm  0.365  1.868µm  6.24 
CMM-8 1  3.5  40  0.214µm  0.247  0.225µm  0.256 
CMM-9 1  3.5  60  0.199µm  0.223  0.212µm  0.246 
 
Results and Discussion 
Particle size and Size distribution 
The optimized batch (CMM 5) had a mean particle diameter [d(4,3)] of 213nm with 
uniformity (absolute deviation from median value) 0.245 (before lyophilization) with 
2.5%w/v of stabilizer and 40%v/v particles. After lyophilization the mean particle diameter 
was still 216nm with uniformity 0.25 (Table 1, 2). Increasing the media volume led to 
slightly higher particle diameters but did not significantly change by increasing the 
concentration of stabilizer. The lowest mean particle diameter was obtained at 8h milling in 
50:50 ratio of milling media. Further stirring ncreased the mean particle diameter of the 
CsA nanosuspension. The resulting nanosuspensions were of uniform particle size in the 
range around 200nm, which is very important for in vivo biodistribution. The particle size 
distribution pattern of the optimized nanosuspension formulation is given in figure 1. 
 
Tab. 2.   Particle diameter of the optimized batch (CMM 5) of lyophilized nanosuspension 
during storage at 2–8°C. 
Time (Months)  Mean Particle size [d(4,3)]  Uniformity 
Initial 0.217µm  0.260 
1   0.268µm  0.372 
2 0.320µm  0.375 
3  0.600µm   1.98  
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Fig. 1.   Size distribution of the optimized batch (CMM 5) of CsA-nanosuspensions. 
The comparison of the bioavailability of CsA from solid lipid nanoparticles and 
nanocrystals revealed low variation in bioavailability from SLN as compared to 
nanocrystals of CsA [21]. Poloxamers appear to exert their effects on P-glycoprotein via 
direct or indirect inhibition, on membrane fluidity, adenosine triphosphate (ATP), depletion 
or on osmolarity [22]. 
Scanning electron microscopy (SEM) 
Scanning electron images reveal a change in appearance of the surface upon formulating 
the nanosuspension. The altered shape might be due to coating of CsA-particles with a 
surfactant/stabilizer layer and creation of an amorphous surface layer due to the high 
attrition and shearing rate [23]. 
A B 
Fig. 2.   Scanning electron image of CsA-nanosuspension CMM 5 at (A) 100X and (B) 
400X magnification. 
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Differential Scanning Calorimetry (DSC)  
The DSC thermograms of Plain drug (CsA) and optimized nanosuspension formulation 
were taken on a Mettler DSC 20 differential scanning colorimeter between 30–200°C at a 
heating rate of 20°C/min. Pure CsA showed melting point at 134.02°C corresponding to its 
melting point [24], whereas in the thermograph pattern of formulation no such peak was 
observed (figure 3) [25]. So it can be concluded that the drug particles were absolutely 
bound by the surfactant molecules [26]. As shown in figure 3 in the DSC of formulation 
sharp transitions at 54.72°C and 168.69°C were observed which correspond to the melting 
points of (poloxamer) [27] and (mannitol) respectively [28].  
 
Fig. 3.   DSC thermograms of (A) Plain drug (CsA) and (B) CsA-nanosuspension  
pH 
For intravenous dosage form the pH should be within physiological pH range. Table 3 
shows the pH of the nanosuspension before and after addition of a cryoprotectant (1:1 
ratio). It was observed that it was in range. 
Tab. 3.   Results of pH, Saturation solubility, Assay and Osmolarity of cyclosporine 
nanosuspension formulation. 
Sr. No.  Parameters  Results 
With Cryoprotectant (Mannitol)  7.49  1. pH 
Without Cryoprotectant (Mannitol)  6.74 
Plain drug (CsA)  34.59µg/ml  2.  Saturation 
solubility  CsA nanosuspension  196.94µg/ml 
3. Drug  content  99.12%w/w 
Practically determined  320.20mOsmol/L  4. Osmolarity 
Theoretically calculated 317.44mOsmol/L 
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Saturation solubility 
The saturation solubility is equilibrium between dissolving molecules (dissolution pressure) 
and re-crystallizing molecules [29]. The saturation solubility increases with decreasing 
particle size according to the Ostwald–Freundlich equation [30]. 
The results of saturation solubility of plain drug (CsA) and lyophilized powder of the CsA-
nanosuspension (see table 3) revealed a saturation solubility of 34.59µg/ml (plain CsA) 
and 196.94µg/ml (CsA-nanosuspension). Thus saturation solubility of CsA as a nano-
suspension is 5.69 fold higher than that of plain CsA. In the present study, particle size of 
CsA has been reduced hence increased the saturation solubility due to increasing the 
surface area of the reduced particles [31]. 
Drug content [32] 
In nanosuspension formulation the drug particles were reduced to nano sized. During the 
formulation process there was not any drug loss step involved, so theoretically the 
formulation was considered as being 100% drug content. As shown in Table 3 the drug 
content was found to be 99.12%w/w. 
Osmolarity  
Intravenous dosage form should be isoosmolar with the blood (250–350mOsmol/L) so the 
optimized nanosuspension formulation was checked for osmolarity and results revealed 
that prepared nanosuspension was isoosmolar with the blood (Table 3). 
Stability Studies 
Fig. 4.   Size distribution of the above optimized batch of nanosuspension during 
storage at 2–8 °C.  
During storage as aqueous dispersions, nanosuspensions sometimes show physical 
instability cause by aggregation. However, crystal growth does not play a role in storage of 
nanosuspensions at room temperature or at 5°C over a period of months. To avoid 
aggregation, formulation should be transferred into a dry product, such as by lyophilization 
or spray-drying. Nanosuspensions can be easily lyophilized and are well re-dispersible
 
[18]. Stability study of nanosuspension formulation was carried out at 2–8°C. The 
optimized batch was stable up to 3 months with slightly increased in the particle size on 
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storage up to 3 months (Table 2). The particle size distribution indicated uniformity initially 
but due to the storage the particles aggregation might have occurred and so particle size 
was increased and uniformity was reduced (Figure 4).  
In vivo study [32–35] 
According to one study, in which a 14-day studies of intravenous administration of 
poloxamer at concentrations up to 0.5 g/kg/day to rabbits was performed and no overt 
adverse effects were noted. A similar study with dogs also showed no adverse effects at 
dosage levels of poloxamer up to 0.5 g/kg/day [28]. 
 
Fig. 5.   Overlaid spectrum of CsA spiked in plasma and blank plasma 
 
Fig. 6.   Overlaid spectrum of CsA detected in plasma samples of the nanosuspension 
and blank plasma 
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In vivo study was performed for estimation of cyclosporine in plasma. Figure 5 shows an 
overlaid spectrum of cyclosporine spiked in plasma and blank plasma, and figure 6 shows 
an overlaid spectrum of cyclosporine detected in plasma sample of nanosuspension and 
blank plasma. 
Figure 7 shows the mean blood concentration versus time profiles after intravenous 
administration of CsA in three different dosage forms namely: free drug, marketed 
microemulsion formulation (Sandimmune® I.V.) and nanosuspension formulation. The 
amount of drug detected in the plasma of different rats at different time points along with 
standard deviation is as shown in the table 4.  
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Fig. 7.   Mean blood concentration-time profiles of CsA following intravenous 
administration 
A peak concentration was reached within 1 hour in all the three formulations but the 
maximum concentration at 1 hour was observed with the marketed formulation (table 4). 
There was no significant difference between the nanosuspension and Microemulsion 
formulation (marketed formulation). The half life of CsA from the intravenously 
administered nanosuspension formulation was greater than the microemulsion formulation 
(Table 5).  
The difference between the nanosuspension and marketed solution was statistically non 
significant (p < 0.05). The difference between the free drug and the marketed solution was 
statistically significant (p > 0.05). In addition, the difference between the free drug and the 
nanosuspension was statistically significant (p > 0.05). The elimination rate constant (Kel) 
was lower for nanosuspension formulation than the other two formulations. Based on this 
work, it is believed that an alternative Nanosuspension formulation for intravenous 
administration can be obtained from which the cyclosporine can exert its clinical effects 
with minimum inter individual variability. From the figure 7 and table 4 and 5 we can say 
that the prepared nanosuspension is equal to that of marketed preparation. 
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Tab. 4.   Blood cyclosporine A concentration in three groups of rats receiving different 
formulations.  
Concentration (µg/ml) 
Product Time  (h) 
1 2 
Mean ± S.D 
0.30  2.8  2.9  2.85 ± 0.070 
1  2.2  2.3  2.25 ± 0.070 
2  1.2  1.1  1.15 ± 0.070 
4  0.8  0.6  0.70 ± 0.141 
8  0.5  0.4  0.45 ± 0.070 
12  0.15  0.13  0.14 ± 0.141 
Free drug 
24  0.1  0.09  0.09 ± 0.070 
0.30  3.1  3.13  3.10 ± 0.021 
1  3.9  4.1  4.00 ± 0.141 
2  2.3  2.1  2.20 ± 0.141 
4  1.9  1.8  1.85 ± 0.070 
8  1.6  1.4  1.50 ± 0.141 
12  1.1  0.9  1.00 ± 0.141 
Marketed sample 
(Sandimmune® 
I.V.) 
24  0.5  0.4  0.45 ± 0.070 
0.30  2.9  3.1  3.00 ± 0.141 
1  3.5  3.6  3.55 ± 0.070 
2  2.5  2.4  2.45 ± 0.070 
4  1.9  1.7  1.80 ± 0.141 
8  1.7  1.6  1.65 ± 0.070 
12  1.4  1.1  1.25 ± 0.212 
Nanosuspension 
24  0.8  0.7  0.75 ± 0.070 
 
 
Tab. 5.   Mean pharmacokinetic parameters of CsA following intravenous administration 
of three dosage forms (dose 300µg per rat) 
 Free  drug  Sandimmune® I.V. 
(Microemulsion)  Nanosuspension 
Cmax (µg/ml)  2.8  3.9  3.5 
T1/2 (h)  2.01  6.867  9.88 
Kel (ml/min/kg) 0.344  0.100  0.07 
Vd   100.49  88.353  97.21 
Total Cl  34.58  8.91  6.89 
AUC   8.67  33.64  44.01 
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Experimental 
Materials 
Cyclosporine was obtained as a gift sample from RPG Lifesciences Ltd. Ankleshwar, India; 
Poloxamer 407 was obtained from BASF, Germany; Zirconium Oxide beads were obtained 
as gift samples from Sun Pharmaceutical Industries Ltd., India; Mannitol, Methanol and 
Tetrahydrofuran were purchased from S.D. Fine Chemicals, India; Acetonitrile (HPLC 
Grade) and Methanol (HPLC Grade) were obtained from Spectrochem Pvt. Ltd., India. 
Methods 
Preparation of Cyclosporine based Nanoparticles 
An attempt was made to prepare stable nanosuspension of Cyclosporine A (CsA) using 
Zirconium Oxide beads as a milling media, Poloxamer 407 as a stabilizer, distilled water 
as an aqueous medium, using Pearl milling technique. The various parameters like effect 
of stirring time, stirring speed and ratio of beads were optimized by keeping the drug: 
Surfactant: Milling media (1:3.0:50) as constant initially and the optimized condition was 
used throughout the study (Tables 6 and 7). These parameters were optimized at 25°C. 
Milling equipment was cleaned using mild soap solution first and after that several washes 
with deionised water were made to remove all traces of detergent. The final wash was 
carried out with distilled water. 
Tab. 6.   Effect of stirring time for the preparation of nanosuspension containing 
cyclosporine 
Batch. No.  Time (h)  Mean particle size [D(4,3)] 
ST1 Initial  (5min.)  19.95µm 
ST2 2  2.739µm 
ST3 4  0.884µm 
ST4 6  0.526µm 
ST5 8  0.230µm 
ST6 10  0.238µm 
ST7 12  0.242µm 
 
Tab. 7.   Effect of Ratio of beads for the preparation of nanosuspension containing 
cyclosporine 
Ratio of beads (Zirconium Oxide) 
Batch. No.  Small Size 
(0.4–0.7mm) 
Big Size 
(1.2–1.7mm) 
Mean particle size 
[D(4,3)] 
 
RB1 100  0  0.435µm 
RB2 75  25  0.364µm 
RB3 50  50  0.237µm 
RB4 25  75  0.534µm 
RB5 0  100  0.685µm 
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Nanosuspension containing cyclosporine was optimized for formulation parameters by 3
2 
factorial designs. Nanosuspensions were prepared by dissolving different concentration of 
surfactant (Poloxamer 407) in distilled water then drug was added directly into the 
surfactant solution and comminuted using Zirconium Oxide beads on a magnetic stirrer. 
The process and formulation parameters were optimized to achieve minimum particle size. 
The coded values and observations of the optimization process by 3
2 factorial designs are 
tabulated in table 8. 
Tab. 8.   3
2 factorial design layout for optimization of nanosuspension containing 
cyclosporine. 
Batch No.  X1 X 2 
CMM-1 3.0  50 
CMM-2 3.0  40 
CMM-3 3.0  60 
CMM-4 2.5  50 
CMM-5 2.5  40 
CMM-6 2.5  60 
CMM-7 3.5  50 
CMM-8 3.5  40 
CMM-9 3.5  60 
X1 – Concentration of Surfactant (Polaxamer 
407) (% w/v) 
X2 – % v/v of Milling Media (Zirconium oxide 
beads) 
 
Lyophilization method 
The optimized nanosuspension (CMM-5) was lyophilized using mannitol (1:1 ratio) as a 
cryoprotectant. Nanosuspension containing ampoules were freeze in deep freezer at –
20°C for 8h (EIE, India) for primary freezing. The ampoules were then transferred to flask 
and the flask was attached to the vacuum adapter of lyophilizer (hetodry winner). The 
solvent was sublimed under a pressure of 80 mmHg for 24h.  
Particle size and Size distribution 
The mean particle size and size distribution of the prepared nanosuspension formulations 
were obtained by using Malvern particle size analyzer SM 2000, which followed Mies 
theory of light scattering. Particle size detection range for Malvern SM 2000 is 0.02 to 2000 
µm. Nanosuspensions were added to the sample dispersion unit containing stirrer and 
stirred at 2000rpm in order to reduce the interparticle aggregation, and laser obscuration 
range was maintained between 10-20%. The average particle sizes were measured after 
performing the experiment for each batch in triplicate.  
Scanning electron microscopy (SEM) 
The lyophilized powder of nanosuspension formulation was kept in the sampling unit as a 
thin film and then photographs were taken at 100X & 400X magnification using Scanning 
Electron Microscope (Jeol, JSM-840 SEM Japan).  
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Differential Scanning Calorimetry (DSC)  
The DSC thermograms of Plain drug (CsA) and optimized nanosuspension formulation 
were taken on a Mettler DSC 20 differential scanning colorimeter between 30–200°C at a 
heating rate of 20°C/min. The thermograms of Plain drug (CsA) and optimized 
nanosuspension formulation are shown in figure 3. 
pH 
Prepared nanosuspension was taken in 10ml beaker and pH was measured using pH 
meter (Digital Instrument Corporation, India). Table 3 shows the pH of the nanosuspension 
before and after addition of cryoprotectant.  
Saturation solubility 
Saturation solubility is a compound-specific constant only depending on the temperature 
and the properties of the dissolution medium. However, below a size of approximately  
1–2 µm, the saturation solubility is also a function of the particle size [29].  
Saturation solubility of Plain drug (CsA) and lyophilized powder of optimized 
nanosuspension formulation were carried out in phosphate buffer pH 7.4 for which 5mg of 
drug and lyophilized powder (weigh equivalent to 5mg of drug) in 2ml phosphate buffer pH 
7.4 were taken separately and were allowed to be stirred in an isothermal shaker (37.0 ± 
1.0°C) for 24h. The stirred samples were further taken in test tubes and centrifuged (Remi) 
at 10000 rpm for 15 minutes. The supernants were collected, diluted 5 times with PBS pH 
7.4 and absorbance were measured at 210nm [32] using UV-Visible spectrophotometer. 
The solubility was measured at 25°C.  
Drug content  
Drug content of nanosuspension formulation was carried out by taking lyophilized powder 
(weigh equivalent to 5mg of drug) in methanol:THF (1:1) mixture, shaken well, Mannitol is 
slightly soluble in methanol:THF (1:1) mixture so it was then centrifuged at 8000rpm for 
10min. The supernatants were taken and diluted with methanol:THF (1:1) mixture and the 
absorbance was measured at 210nm. The drug content was calculated using the 
calibration curve. The results are shown in Table 3. 
Osmolarity  
Practically Osmolarity was measured using Osmometer and theoretically it was calculated 
using following formula: 
100  x   weight Molecular
1000  x  species   of   No.  x  gm/lit   in   Weight
    (mOsmol/L)   Osmolarity =  
Stability study 
Stability of optimized nanosuspension formulation containing cyclosporine was evaluated 
by determining change in particle size during storage at 2-8°C. Any change in particle size 
of nanosuspension formulation was observed using Malvern Mastersizer 2000 at periodic 
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In vivo study
 [33] 
Three groups of two albino rats were taken for the study. The study was carried out at the 
Mercury Laboratories, Vadodara. All experiments and protocols described in this study 
were approved by the Institutional Animal Ethics Committee of MS University of Baroda 
and are in accordance with the Committee for Purpose of Control and Supervision of 
Experiments on Animals (CPCSEA), Ministry of Social Justice and Empowerment, 
Government of India with the permission number 404/01/a/CPCSEA. The rats were fasted 
overnight and then each group was given a different cyclosporine formulation viz. free 
drug, marketed sample of cyclosporine namely Sandimmune® I.V. (Microemulsion) and 
Nanosuspension (Table 9). The normal human dose of Cyclosporine is 5 mg/kg of body 
weight. This dose was converted into animal dose by using the formula given below: - 
HED = Animal dose in mg/kg /(animal body weight in kg/human body weight in kg)
1/3  
Where HED =Human equivalent dose 
  Animal body weight = 0.320kg 
  Human body weight = 60kg 
By using this formula, dose of Cyclosporine given to rats was obtained 300µg. Hence, 
each of 3 formulations was administered at the dose of 300µg Cyclosporine. The blood 
samples were collected at 30min, 1h, 2h, 4h, 8h, 12h and 24h following I.V. administration. 
100μl of plasma was taken in a 0.5ml micro centrifuge tube and 100μl of acetonitrile was 
added into it to precipitate the proteins present in plasma. The tube was vortexed for 5 min 
followed by centrifugation at 15000 rpm for 10 min. The supernatant was taken and 50μl 
was injected into Shimadzu-AS HPLC system. The calibration curve of plasma spiked with 
cyclosporine was taken in a range of 0.06 to 50 ppm. Data analysis was done using 
QUICK CALC software. Statistical analysis was done using a two tail paired t-test for 
determining statistical significance (p < 0.05). All results were expressed as the mean ± 
standard deviation (S.D.).  
Tab. 9.   Different formulation and volume administered to different groups of animals.  
Animal 
No.  Formulation  Body weight 
(gm) 
Volume to be 
injected(ml) 
1 320  0.28 
2 
Free drug 
338 0.30 
1 318  0.28 
2 
Microemulsion 
(Sandimmune® I.V.)  326 0.29 
1 340  0.30 
2 
Nanosuspension 
332 0.29 
Conclusion 
From the above results we have concluded that the present investigation of 
nanosuspension formulation containing CsA can be an alternative dosage form of 
intravenous microemulsion formulation by avoiding a hypersensitivity reaction caused by 
Cremophore EL 35. All Pharmacokinetic parameters show favorable results. It can 
modulate the disposition of drug in the body and potentially improve the safety & efficacy 
profile of drug. It is a simple, cost effective and scalable method as compared to other 
methods.  358 M.  Nakarani  et al.:  
Sci Pharm. 2010; 78: 345–361. 
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